Boundless Bio Stock
Boundless Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Zachary Hornby
- Employees
- 28
- Market cap
- $53 M
- IPO
- 28/03/2024
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an…
Boundless Bio stock: price history
1D
-0.4%
1W
-7.5%
1M
-17.0%
6M
+48.1%
YTD
+95.0%
1Y
+66.0%
2Y
-23.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~26% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Boundless Bio
Analyst assessment of Boundless Bio
0
STRONG BUY
6
BUY
13
HOLD
1
SELL
0
STRONG SELL
20
TOTAL · Hold
As of: 11/08/2025
Boundless Bio stock metrics
P/E
-0.82
P/B
0.8
EV/EBITDA
-0.53
RETURN ON EQUITY
-35.9%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.9%
FLOAT SHARES
17,503,051
AVG. DAILY VOLUME (30D)
169,026
Insider transactions (SEC)
TANG KEVIN
TANG KEVIN
TANG KEVIN
TANG KEVIN
TANG KEVIN
Institutional holders
Comparable stocks
Frequently asked questions about Boundless Bio stock
What does Boundless Bio do?
Boundless Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Zachary Hornby, the company employs around 28 people.
The IPO was on 28/03/2024; the stock trades on NASDAQ under the ticker BOLD.
What do analysts say about Boundless Bio stock?
20 analysts rate the stock, the consensus is Hold (as of 11/08/2025).
This is an external assessment, not a statement by Market Jury.
When does Boundless Bio report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -26% stronger than usual.
Does Boundless Bio pay a dividend?
No, Boundless Bio currently does not pay a dividend.
Which stocks are comparable to Boundless Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Boundless Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Boundless Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.